Los Angeles, USA , May 17, 2021 (GLOBE NEWSWIRE) -- Revolutionary Treatment for Hemophilia B Shows Promise in Clinical TrialsNovel Hemophilia B pipeline therapeutics include...
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent (dupilumab) in children aged 6 to...
Regeneron Pharmaceuticals and Sanofi announce detailed results from a Phase 3 trial in which Dupixent(dupilumab) significantly reduced...
Sanofi's price per share closed at $51.50 yesterday. One year ago its price was $49.87.
Should Sanofi's stock trade in the range of $40 to $65 this year, its recent $49.67 price might rise by $10.64 to reach $60.00 by April 5, 2022.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 156.10 | 159.65 | 155.35 | -1.20 | -0.76% | 2.92M | London | |||
| 23.00 | 23.74 | 21.80 | -0.26 | -1.12% | 11.56M | London | |||
| 53.90 | 55.20 | 53.80 | -0.64 | -1.17% | 12.69M | London | |||
| 52.40 | 55.80 | 52.20 | -0.80 | -1.50% | 1.79M | London | |||
| 2,816.50 | 2,842.50 | 2,792.00 | -10.5 | -0.37% | 2.03M | London | |||
| 37.50 | 37.70 | 37.70 | +2.00 | +5.63% | 3.13M | London | |||
| 325.15 | 327.50 | 318.95 | +0.55 | +0.17% | 24.97M | London | |||
| 1,495.50 | 1,531.50 | 1,489.50 | -19.00 | -1.25% | 2.49M | London | |||
| 436.00 | 436.40 | 429.60 | +3.40 | +0.79% | 282.47K | London | |||
| 8,082.00 | 8,214.00 | 8,044.00 | -4.0 | -0.05% | 165.08K | London | |||
| 3,517.00 | 3,569.00 | 3,497.00 | +5.0 | +0.14% | 350.11K | London | |||
| 141.00 | 142.00 | 140.98 | -1.00 | -0.70% | 241.41K | London | |||
| 1,118.00 | 1,148.00 | 1,118.00 | -12.50 | -1.11% | 2.45M | London | |||
| 1,592.60 | 1,633.20 | 1,579.40 | -2.2 | -0.14% | 1.25M | London | |||
| 406.70 | 411.30 | 406.70 | -2.20 | -0.54% | 5.73M | London |
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.